Life Sciences & Healthcare
We provide highly specialized, multidisciplinary legal advisory services to companies driving innovation and development in the sector. We work closely with pharmaceutical companies, biotechnology firms, CROs, medtechs, medical device manufacturers, vaccine developers, healthtechs, healthcare service providers, and leaders in precision and preventive medicine, among other key industry players. Our team combines deep technical and legal knowledge with strong practical experience, understanding the complex regulatory, commercial, and technological nuances affecting each segment
Life Sciences & Healthcare
We provide highly specialized, multidisciplinary legal advisory services to companies driving innovation and development in the sector. We work closely with pharmaceutical companies, biotechnology firms, CROs, medtechs, medical device manufacturers, vaccine developers, healthtechs, healthcare service providers, and leaders in precision and preventive medicine, among other key industry players. Our team combines deep technical and legal knowledge with strong practical experience, understanding the complex regulatory, commercial, and technological nuances affecting each segment
By continuously adopting advanced technology, implementing sophisticated sustainability practices, and proactively working to improve patient access to vital products, services, and solutions, this industry holds an undeniably significant position in the global economy
By continuously adopting advanced technology, implementing sophisticated sustainability practices, and proactively working to improve patient access to vital products, services, and solutions, this industry holds an undeniably significant position in the global economy
Our take on the industry
The emergence of new technologies is propelling the market toward a comprehensive and irreversible transformation. Notable are the rapid advances in digitalization and the rise of new business paradigms in medical technology and the pharmaceutical sector.
Innovative therapies, such as cell and gene therapy, as well as medtech solutions, are expected to continue generating cutting-edge developments in this field. Venture capital remains a vital catalyst to sector development, and collaborative ventures and licensing agreements among industry players are emerging as promising investment pathways. In the meantime, market dynamics remain volatile, driven by shifts in capital flows, geopolitics, global inflationary pressures, and economic uncertainty. Industry-specific challenges – such as competition for talent, the politicization of drug pricing, healthcare litigation, diversification in clinical trials, and growing pressure to demonstrate ESG commitment – also make it difficult to clearly anticipate the horizon.
Nevertheless, the coming years hold significant potential. We are seeing a growing number of transactions, advances in innovative therapies and medical technologies, and a strategic landscape marked by notable B2B collaborations, licensing agreements, and divestitures. An increased focus on contractual arrangements within supply chains further underscores the industry’s ethos of resilience. Successfully navigating this dynamic terrain requires skillful maneuvering and expertise in addressing constantly evolving challenges.
Our take on the industry
The emergence of new technologies is propelling the market toward a comprehensive and irreversible transformation. Notable are the rapid advances in digitalization and the rise of new business paradigms in medical technology and the pharmaceutical sector.
Innovative therapies, such as cell and gene therapy, as well as medtech solutions, are expected to continue generating cutting-edge developments in this field. Venture capital remains a vital catalyst to sector development, and collaborative ventures and licensing agreements among industry players are emerging as promising investment pathways. In the meantime, market dynamics remain volatile, driven by shifts in capital flows, geopolitics, global inflationary pressures, and economic uncertainty. Industry-specific challenges – such as competition for talent, the politicization of drug pricing, healthcare litigation, diversification in clinical trials, and growing pressure to demonstrate ESG commitment – also make it difficult to clearly anticipate the horizon.
Nevertheless, the coming years hold significant potential. We are seeing a growing number of transactions, advances in innovative therapies and medical technologies, and a strategic landscape marked by notable B2B collaborations, licensing agreements, and divestitures. An increased focus on contractual arrangements within supply chains further underscores the industry’s ethos of resilience. Successfully navigating this dynamic terrain requires skillful maneuvering and expertise in addressing constantly evolving challenges.
Opportunities
- China
- Venture capital remains essential for sector financing
- Small- and mid-sized transactions are prevalent, rather than mega-deals
- Divestitures of non-core assets are increasingly common
- Strategic B2B partnerships
- Regulatory convergence
- Innovative therapies, such as cell and gene therapies, continue to advance
- Generative AI
- Medtech solutions are expanding rapidly
- Carbon market
Challenges
- Market correction in the post-pandemic context, requiring a continuous cycle of experimentation, learning, and action
- High volatility and macroeconomic pressures
- Sustainability
- Financial returns in emerging markets
- Revenue loss due to patent expirations or competition from generics
- Rising R&D costs
- Strict oversight of price controls and the entry of generics or biosimilars
- Healthcare litigation
- China
Macrotrends
- International Health Collaboration, with China leading the way
- Clinical research, as an effort to offset market share loss due to patent expirations
- Regulatory convergence
- Patient data interoperability / Real-World Data (RWD)
- Precision Medicine
- Preventive Medicine
- Generative AI
- Medtechss
- Wearable technology / health gadgets
- Carbon market
Work Highlights
New Horizons in Genetic and Oncology Therapy Research in Brazil
We play a key role in providing specialized guidance to a leading U.S. biopharmaceutical company, working closely on corporate strategy development, establishment of strategic partnerships, and ensuring regulatory compliance in innovative genetic and oncology clinical trials conducted in Brazil
Expanded Access to Treatments for Rare Diseases
As leaders in regulation, we support the development of initiatives aimed at expanding access to treatments for rare diseases on behalf of a major global pharmaceutical company. We refine market entry strategies, forge strategic alliances, and implement measures to significantly improve the availability of these vital therapies in Brazil
Shaping Responsible Generative AI Policies
In partnership with a global pharmaceutical giant, we contribute to the formulation of ethical and regulatory policies guiding the responsible use of generative artificial intelligence. Our work ensures regulatory compliance and promotes ethical deployment of this innovative technology across all operations, establishing clear and transparent guidelines
Guiding the Implementation of Health Solutions in Brazil
We facilitate the market entry of a leading infection prevention solutions company into Brazil. By providing specialized guidance on asset acquisition, tax strategies, regulatory compliance, client management, and operational structuring, we help ensure a successful and sustainable entry into the local market
Carbon Neutrality in Support of Health and Well-being
We collaborate with a major investment fund and a Brazilian company committed to the energy transition, health, and well-being. Our work supports the decarbonization journey through the development and implementation of innovative programs for generating and offsetting carbon credits, aligned with principles of sustainability and regeneration
Work Highlights
New Horizons in Genetic and Oncology Therapy Research in Brazil
We play a key role in providing specialized guidance to a leading U.S. biopharmaceutical company, working closely on corporate strategy development, establishment of strategic partnerships, and ensuring regulatory compliance in innovative genetic and oncology clinical trials conducted in Brazil
Expanded Access to Treatments for Rare Diseases
As leaders in regulation, we support the development of initiatives aimed at expanding access to treatments for rare diseases on behalf of a major global pharmaceutical company. We refine market entry strategies, forge strategic alliances, and implement measures to significantly improve the availability of these vital therapies in Brazil
Shaping Responsible Generative AI Policies
In partnership with a global pharmaceutical giant, we contribute to the formulation of ethical and regulatory policies guiding the responsible use of generative artificial intelligence. Our work ensures regulatory compliance and promotes ethical deployment of this innovative technology across all operations, establishing clear and transparent guidelines
Guiding the Implementation of Health Solutions in Brazil
We facilitate the market entry of a leading infection prevention solutions company into Brazil. By providing specialized guidance on asset acquisition, tax strategies, regulatory compliance, client management, and operational structuring, we help ensure a successful and sustainable entry into the local market
Carbon Neutrality in Support of Health and Well-being
We collaborate with a major investment fund and a Brazilian company committed to the energy transition, health, and well-being. Our work supports the decarbonization journey through the development and implementation of innovative programs for generating and offsetting carbon credits, aligned with principles of sustainability and regeneration
Areas of Practice
Get to know our leaders
Bruna Rocha
Partner
Eugênie Caroit
Counsel
Jessica Filka
Counsel
Bruna Rocha
Partner
Eugênie Caroit
Counsel
